Figure 5 from PARP Inhibitors Differentially Regulate Immune Responses in Distinct Genetic Backgrounds of High-Grade Serous Tubo-Ovarian Carcinoma

PARPi–induced CXCL10 gene expression levels are not affected by STING knockdown in a cGAS-defective cell line. A, The expression levels of STING and cGAS were measured by western blot analysis 48 hours after DMSO treatment. ERK2 was used as a loading control. Results shown are from one of two independent experiments. B–E, OVCAR3 and CAOV3 were transfected with control or STING siRNA for 24 hours. Cells were re-plated the next day and treated 48 hours after transfection with DMSO, 10 μmol/L veliparib, or 2 μmol/L talazoparib. Total RNA was extracted from cell pellets that were collected 48 hours after drug treatment, and then 1 μg of RNA was reverse transcribed to cDNA. Quantitative real-time RT-PCR was utilized to measure the gene expression levels of TMEM-173 (STING), CXCL10, and GAPDH. T tests were performed between the control siRNA DMSO-treated group and the five other conditions. A t test was also performed between the control siRNA veliparib- vs. STING siRNA veliparib-treated groups and the control siRNA talazoparib- vs. STING siRNA talazoparib-treated groups. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not statistically significant.